Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03585348|
Recruitment Status : Recruiting
First Posted : July 13, 2018
Last Update Posted : April 23, 2019
|Condition or disease||Intervention/treatment|
|Neuromuscular Blockade Residual Curarisation, Postoperative Surgery Under General Anaesthesia||Other: Neuromuscular blocking agents|
More than 400 million people receive neuromuscular blocking agents (NMBA) annually, either in the operating theatre to optimize surgical conditions, or in the intensive care unit to facilitate mechanical ventilation in those with patient-ventilator asynchrony. NMBA have been associated with increased morbidity secondary to postoperative residual neuromuscular blockade. The incidence of residual blockade is about 20-60% of patients and depends on compound and dose of NMBA reversal agent used. Despite disagreements over guidelines and thresholds to define the optimal strategy to optimize surgical conditions, there is growing evidence that very high doses of NMBA and neostigmine put the patients at risk of respiratory complications and hospital readmission. The investigators have recently shown that dedicated quality improvement initiatives substantially improve the utilization of non-depolarizing muscle relaxants and their reversal agents.
This is a retrospective, observational, multi-centric cohort study based on on-file hospital data from two institutions, Massachusetts General Hospital and Beth Israel Deaconess Medical Center, Boston, Massachusetts. The investigators will compare the utilization of NMBA cross different groups of anesthesia providers (anesthesiologists, anesthesia residents, CRNAs) who provided anesthesia care in at least 100 cases in their institution. The investigators will control our provider-specific findings for patient-, procedure-, and hospital-specific differences in NMBA utilization.
Primary objective is to determine the variability between individual anesthesia providers in the use of neuromuscular blocking drugs and reversal agents (neostigmine at Massachusetts General Hospital/MGH and neostigmine or sugammadex at Beth Israel Deaconess Medical Center/BIDMC) across provider-types (attending physician, resident, nurse anesthetists (CRNA)), experience level (number of cases done in an institution), and hospitals (MGH, BIDMC).
Potential mechanisms of the provider variability will then be examined, such as providers´age, gender, race, profession, employment status and time of the procedure (surgery conducted during daytime versus nighttime).
Additionally, the investigators will examine if the provider variance in the use of NMBA, neostigmine, and sugammadex (based on mean dose across providers and individual mean dose given for standardized surgical procedures) is associated with respiratory complications and direct costs of care.
|Study Type :||Observational|
|Estimated Enrollment :||250000 participants|
|Official Title:||Importance of Understanding Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal Agents|
|Actual Study Start Date :||June 29, 2018|
|Estimated Primary Completion Date :||August 2019|
|Estimated Study Completion Date :||December 2019|
The estimated cohort consists of 317.000 adult patients who are intubated for a non-cardiac surgery and extubated at the end of the case at Beth Israel Deaconess Medical Center (205.000) as well as Massachusetts General Hospital (112.000) and received treatment by anesthesia and surgical providers who have completed at least 50 anesthesias and surgeries at their respective institution, respectively.
Other: Neuromuscular blocking agents
Neuromuscular blocking agent ED95 equivalent dose by provider
- Neuromuscular blocking agents ED95 equivalent dose or reversal agents dose (neostigmine and/or sugammadex) [ Time Frame: During surgery, maximum of 24 hours ]Neuromuscular blocking agent ED95 equivalent dose defined as the median effective dose required to achieve a 95% reduction in maximal twitch response from baseline.
- Respiratory Complications [ Time Frame: Up to 7 days after surgery ]Respiratory complications defined as pneumonia, respiratory failure, pulmonary edema, or reintubation.
- Direct costs of care [ Time Frame: During hospital stay, on average 4 days, and no longer than 1 year ]Direct costs of care defined as costs incurred from admission to discharge day.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03585348
|Contact: Matthias Eikermann, MD PhD||(617) email@example.com|
|Contact: Maria Patrocinio, MDfirstname.lastname@example.org|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Timothy Houle, PhD THOULE1@mgh.harvard.edu|
|Beth Israel Deaconess Medical Center||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Matthias Eikermann, MD PhD 617-632-7034 email@example.com|
|Principal Investigator:||Matthias Eikermann, MD PhD||Beth Israel Deaconess Medical Center|